3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Stomach Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
2
HER2-positive Gastric Cancer
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Cancer Recurrent
1
Neoplasms
1
Muscle Invasive Bladder Carcinoma
1
Muscle Invasive Bladder Cancer (MIBC)
1
Muscle Invasive Bladder Cancer
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Lung Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
HER2-low Breast Cancer
1
HER2
1
Gastric Adenocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Interventions
Gastrectomy
4
Taxes
3
sintilimab
2
S 1 (combination)
2
Paclitaxel
2
Oxaliplatin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Drug Therapy
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tipiracil
1
taxane
1
pembrolizumab
1
durvalumab
1
disitamab vedotin
1
cabozantinib
1
apatinib
1
XELOX
1
Trifluridine
1
Tegafur
1
Tadalafil
1
SHR-1701
1
Resistance Training
1
Radiotherapy
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastric Adenocarcinoma
×
disitamab vedotin
×
Clear all
NCT07507526
2026-04-02
DTP-HER2
Sun Yat-sen University
Phase 2
Not yet recruiting
76 enrolled